QPP Measure #506
Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint Inhibitor Therapy
Percentage of patients, aged 18 years and older, with a diagnosis of metastatic non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (HNSCC) on first-line immune checkpoint inhibitor (ICI) therapy, who had a positive PD-L1 biomarker expression test result prior to giving ICI therapy.
The following codes apply for this QPP measure:
HCPCS Codes | |||
Code | Description | ||
---|---|---|---|
M0001 | Advancing cancer care mips value pathways |
Thank you for choosing Find-A-Code, please Sign In to remove ads.